Focuses on developing treatments for Alzheimer's disease and other neurodegenerative disorders.
Alzamend Neuro, Inc. is an early-stage biopharmaceutical company headquartered in Atlanta, Georgia, dedicated to advancing treatments for neurodegenerative and psychiatric disorders. At the forefront of its pipeline is AL001, currently undergoing Phase II clinical trials. This therapeutic combines lithium, proline, and salicylate to target Alzheimer's disease, bipolar disorder, post-traumatic stress disorder, major depressive disorder, and other related conditions.
Additionally, Alzamend Neuro is progressing AL002, which has completed the preclinical stage. This innovative approach utilizes a mutant-peptide sensitized cell as a therapeutic vaccine, aiming to restore the immune system's ability to combat Alzheimer's disease effectively. These developments underscore the company's commitment to pioneering novel therapies that address critical unmet needs in neurological health.
Founded in 2016, Alzamend Neuro continues to expand its research and development efforts, leveraging cutting-edge science to tackle the complexities of neurodegenerative diseases. With a strong emphasis on innovative treatments and patient-centric care, the company remains dedicated to improving the lives of individuals affected by Alzheimer's and related psychiatric disorders globally.